Drug Safety EvaluationWiley, 2002 M04 18 - 1007 pages A comprehensive safety guide to all aspects of the drug development process Drug Safety Evaluation presents an all-inclusive, practical guide for those who are responsible for ensuring the safety of drugs and biologics for patients, for health care providers, for those involved in the manufacture of medicinal products, and for all those who need to understand how the safety of these products is evaluated. Individual chapters address specific approaches to evaluating hazards, including problems that are encountered and their solutions. Author Shayne Gad draws upon over twenty years of experience in toxicology, drug development, and risk assessment, explaining the scientific and philosophical bases for evaluating specific concerns (carcinogenicity, development toxicity, etc.) to provide both understanding and guidance for approaching new problems. Containing information specifically relevant to the pharmaceutical and biotechnology industries, Drug Safety Evaluation covers a wide variety of topics, including: * Acute toxicity testing in pharmaceutical safety evaluation * Genotoxicity * Safety assessment of inhalant drugs * Immunotoxicology in pharmaceutical development * Large animal studies * Evaluation of human tolerance and safety in clinical trials Drug Safety Evaluation provides a road map for safety assessment as an integral part of the development of new drugs and therapeutics. |
From inside the book
Results 1-3 of 75
Page 13
... activity or several activities on any workday during a project . The average daily labor requirement is one example ... activity that uses no time or resources . The time it takes to complete an activity . The earliest time an activity ...
... activity or several activities on any workday during a project . The average daily labor requirement is one example ... activity that uses no time or resources . The time it takes to complete an activity . The earliest time an activity ...
Page 17
... activity ) . It is then possible to design the assay so as to optimize the following characteristics . 1 ... activity evidence over structural classes or to study quantitative structure- activity relationships ( QSARs ) . Quantitative ...
... activity ) . It is then possible to design the assay so as to optimize the following characteristics . 1 ... activity evidence over structural classes or to study quantitative structure- activity relationships ( QSARs ) . Quantitative ...
Page 115
... activities will be found instead . Compounds showing the highest ( beneficial ) or lowest ( adverse ) activity will proceed to the next assay or tier of tests in the series , and may be used as lead compounds in a new cycle of testing ...
... activities will be found instead . Compounds showing the highest ( beneficial ) or lowest ( adverse ) activity will proceed to the next assay or tier of tests in the series , and may be used as lead compounds in a new cycle of testing ...
Contents
Regulation of Human Pharmaceutical Safety | 30 |
Building and Maintaining Data | 99 |
Screens in Safety and Hazard Assessment | 112 |
Copyright | |
22 other sections not shown
Other editions - View all
Common terms and phrases
absorption activity administration adverse aerosols agents analysis and/or antibody antigen appropriate assay biological blood body weight carcinogenicity carcinogenicity studies cells chemical chromosome clinical trials concentration culture dermal detect determine developmental toxicity disease dosage drug effects endpoints evaluation example excipients exposure factors function gene genotoxicity guidelines hepatocytes human immune immunotoxicity increase inhalation injection irritation laboratory lethality liver macrophages measure metabolism metabolites methods mice minipigs molecules monoclonal antibodies mouse mutagenicity mutation nonrodent normal number of animals observed oral organ parameters patients pharmaceutical pharmacokinetic pharmacological Phase plasma potential preclinical protein protocol rabbits rats regulations regulatory renal response rodent route route of administration safety assessment sample screen selection sensitivity significant skin specific statistical substance Table techniques teratogenicity Teratology test article therapeutic tissue toxicity toxicity studies toxicity testing Toxicol toxicology treatment tumor variables vitro vivo xenobiotic